Ainos (NASDAQ:AIMD) Director Sells $208,977.20 in Stock

Ainos, Inc. (NASDAQ:AIMD) Director Ting-Chuan Lee sold 109,988 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $1.90, for a total value of $208,977.20. Following the transaction, the director directly owned 807,417 shares in the company, valued at approximately $1,534,092.30. This represents a 11.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ainos Trading Down 19.0%

Shares of AIMD traded down $0.60 during mid-day trading on Wednesday, reaching $2.56. 1,873,740 shares of the company’s stock traded hands, compared to its average volume of 893,030. The stock’s 50-day moving average is $1.67 and its two-hundred day moving average is $1.83. Ainos, Inc. has a 12 month low of $1.26 and a 12 month high of $4.50. The company has a current ratio of 0.55, a quick ratio of 0.50 and a debt-to-equity ratio of 1.58.

Ainos (NASDAQ:AIMD) last released its earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ainos has a consensus rating of “Sell”.

Institutional Trading of Ainos

Large investors have recently modified their holdings of the company. DRW Securities LLC boosted its holdings in shares of Ainos by 272.6% in the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after purchasing an additional 48,439 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Ainos by 13.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after purchasing an additional 7,700 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Ainos in the third quarter valued at approximately $80,000. Finally, Mariner LLC purchased a new stake in shares of Ainos in the fourth quarter valued at approximately $37,000.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.